Biologics for eosinophilic otitis media: a retrospective case study in a multidisciplinary center.
Asthma
Biologics
CRSwNP
Otitis media
Type 2 inflammatory disease
Urticaria
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
25
07
2024
accepted:
26
08
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
13
9
2024
Statut:
aheadofprint
Résumé
Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media characterized by eosinophilic accumulation in the middle ear mucosa and effusion. It is refractory to conventional treatments and is strongly associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The diagnostic criteria for EOM were established by IINO in 2011. With the recognition of type 2 inflammatory diseases, the gold standard of treatment is the systemic and topical administration of corticosteroids. Recently, several retrospective studies have demonstrated the efficacy of biologic treatments in EOM. We aimed to share our experience regarding the response of EOM after the use of biologics. This is a retrospective observational analysis including patients with refractory EOM treated with different biologics (benralizumab, omalizumab, mepolizumab, dupilumab) for concomitant severe asthma, urticaria and/or severe uncontrolled CRSwNP from 2011 to 2023. Treatment effectiveness in terms of EOM severity was measured using medical Global Evaluation of Treatment Effectiveness (GETE). We illustrated 4 clinical cases of uncontrolled comorbid EOM and demonstrated the complexity of multidisciplinary medical pathway with good response to biologics. We also observed that response to EOM and CRSwNP does not always follow that of asthma. The results of our small sample were consistent with those found in the literature and showed control of EOM with biologics. We need a larger multicentric sample and methodology to confirm these results and to compare the efficacy of different biologics.
Identifiants
pubmed: 39271591
doi: 10.1007/s00405-024-08949-7
pii: 10.1007/s00405-024-08949-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M (2011) Diagnostic criteria for eosinophilic otitis media, a newly recognised middle ear disease. Auris Nasus Larynx 38:456–461
doi: 10.1016/j.anl.2010.11.016
pubmed: 21251776
Tomioka S, Kobayashi T, Takasaka T (1997) Intractable Otitis Media in patients with bronchial asthma (Eosinophilic Ottis Media). In: Sanna M (ed) Cholesteatoma and mastoid surgery. CICI Edizioni International, Rome, pp 851–853
Iino Y (2023) Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris Nasus Larynx 50(4):479–489. https://doi.org/10.1016/j.anl.2022.11.004
doi: 10.1016/j.anl.2022.11.004
pubmed: 36528403
Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P (2012) Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN European survey. Allergy 67(1):91–98. https://doi.org/10.1111/j.1398-9995.2011.02709.x
doi: 10.1111/j.1398-9995.2011.02709.x
pubmed: 22050239
Ryu G, Kim DW (2020) Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. ;20(1):1–8. https://doi.org/10.1097/ACI.0000000000000588 . PMID: 31567293
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, ZhuR et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomised phase 3 trials. J Allergy Clin Immunol 146(3):595–605
doi: 10.1016/j.jaci.2020.05.032
pubmed: 32524991
Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C et al (2021) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomised, placebo-controlled trial. J Allergy Clin Immunol S0091–6749(21):01459
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results of two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638–1650. https://doi.org/10.1016/S0140-6736(19)31881-1
doi: 10.1016/S0140-6736(19)31881-1
pubmed: 31543428
Van der Lans RJL, van Spronsen E, Fokkens WJ, Reitsma S (2021) Complete remission of severe eosinophilic otitis media with dupilumab: a case report. Laryngoscope 131(12):2649–2651. https://doi.org/10.1002/lary.29730 . Epub 2021 Jul 3. PMID: 34216146; PMCID: PMC9292739
doi: 10.1002/lary.29730
pubmed: 34216146
pmcid: 9292739
Iino Y, Sekine Y, Yoshida S, Kikuchi S (2021) Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma. Auris Nasus Larynx 48(3):353–360. https://doi.org/10.1016/j.anl.2020.09.001 . Epub 2020 Sep 14. PMID: 32943257
doi: 10.1016/j.anl.2020.09.001
pubmed: 32943257
De Corso E, Montuori C, Settimi S, Mele DA, Cantiani A, Corbò M, Cantone E, Paludetti G, Galli J (2022) Efficacy of biologics in refractory eosinophilic otitis media associated with bronchial asthma or severe uncontrolled CRSwNP. J Clin Med 11(4):926. https://doi.org/10.3390/jcm11040926 . PMID: 35207196; PMCID: PMC8879230
doi: 10.3390/jcm11040926
pubmed: 35207196
pmcid: 8879230
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER et al (2014) International ERS/ATS guidelines for the definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373. https://doi.org/10.1183/09031936.00202013
doi: 10.1183/09031936.00202013
pubmed: 24337046
Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, Louis R (2010) Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥ 3% in a cohort of unselected patients with asthma. Thorax 65(12):1039–1044. https://doi.org/10.1136/thx.2009.124925 . Epub 2010 Jul 29. PMID: 20671307
doi: 10.1136/thx.2009.124925
pubmed: 20671307
Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R (2013) Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 13:11. https://doi.org/10.1186/1471-2466-13-11 . PMID: 23442497; PMCID: PMC3657295
doi: 10.1186/1471-2466-13-11
pubmed: 23442497
pmcid: 3657295
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reltsma S, Mullol J, Bachert C, Alobid I, Baroody F et al (2020) European position paper on rhinosinusitis and nasal polyps. Rhinology 29:1–464
Fokkens WJ, De Corso E, Backer V, Bernal-Sprekelsen M, Bjermer L, von Buchwald C, Chaker A, Diamant Z, Gevaert P, Han J, Hopkins C, Hox V, Klimek L, Lund VJ, Lee S, Luong A, Mullol J, Peters A, Pfaar O, Reitsma S, Toppila-Salmi S, Scadding GK, Sedaghat AR, Viskens AS, Wagenmann M, Hellings PW (2024) EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology. ;62(3):287–298. https://doi.org/10.4193/Rhin23.415 . PMID: 38217529
Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S (2007) Prediction and assessment of response to omalizumab in patients with severe allergic asthma. Respir Med. ;101(7):1483-92. https://doi.org/10.1016/j.rmed.2007.01.011 . Epub 2007 Mar 6. PMID: 17339107
Shevchik E, Svistushkin V, Nikiforova G, Zolotova A (2022) Eosinophilic Otitis Media: modern aspects of Pathogenesis, clinical features, diagnosis and treatment. Indian J Otolaryngol Head Neck Surg 74(Suppl 1):132–140. https://doi.org/10.1007/s12070-020-01903-z . Epub 2020 Jun 18. PMID: 36032916; PMCID: PMC9411392
doi: 10.1007/s12070-020-01903-z
pubmed: 36032916
Kim SK, Park MW, Min C, Park IS, Park B, Byun SH, Choi HG, Hong SJ (2021) Increased risk of chronic otitis media in patients with chronic rhinosinusitis: a longitudinal follow-up study using a national health screening cohort. Rhinology. ;59(3):292–300. https://doi.org/10.4193/Rhin20.363 . PMID: 33315021
Bartier S, Béquignon E, Thibaut de Ménonville C, Verillaud B, Evrard D, Léger M, Papon JF, Coste A, Taillé C (2023) Otitis media in severe asthma associated with chronic rhinosinusitis with nasal polyps: a new therapeutic target for biologics. J Asthma. ;60(1):139–144. https://doi.org/10.1080/02770903.2022.2033262 . Epub 2022 Feb 3. PMID: 35073225
Klain A, Indolfi C, Dinardo G, Licari A, Cardinale F, Caffarelli C, Manti S, Ricci G, Pingitore G, Tosca M, Decimo F (2021) Miraglia Del Giudice M. United airway disease. Acta Biomed 92(S7):e2021526. https://doi.org/10.23750/abm.v92iS7.12399 . PMID: 34842594; PMCID: PMC9431894
doi: 10.23750/abm.v92iS7.12399
pubmed: 34842594
pmcid: 9431894
Grossman J (1997) One airway, one disease. Chest. ;111(2 Suppl):11S-16S. https://doi.org/10.1378/chest.111.2_supplement.11s . PMID: 9042022
Shaaban R, Zureik M, Soussan D, Antó JM, Heinrich J, Janson C, Künzli N, Sunyer J, Wjst M, Burney PG, Neukirch F, Leynaert B (2007) Allergic rhinitis and development of bronchial hyperresponsiveness: a population-based study. Am J Respir Crit Care Med. ;176(7):659 – 66. https://doi.org/10.1164/rccm.200703-427OC . Epub 2007 Jul 5. PMID: 17615387
Tohidinik HR, Mallah N, Takkouche B (2019) History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis. World Allergy Organ J 12(10):100069. https://doi.org/10.1016/j.waojou.2019.100069 PMID: 31660100; PMCID: PMC6807062
doi: 10.1016/j.waojou.2019.100069
pubmed: 31660100
pmcid: 6807062
De Vittori V, Pacilio A, Indinnimeo L, Marazzato M, De Castro G, Brindisi G, Schiavi L, Tosca M, Duse M, Zicari AM (2019) Coexistence of asthma and rhinitis: does rhinitis impair asthma control in children? Allergy Asthma Proc. ;40(3):e8-e13. https://doi.org/10.2500/aap.2019.40.4219 . PMID: 31018900
Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P, Bousquet J (1999) Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med. ;159(2):588 – 95. https://doi.org/10.1164/ajrccm.159.2.9801022 . PMID: 9927377
Ehnhage A, Olsson P, Kölbeck KG, Skedinger M, Dahlén B, Alenius M, Stjärne P, NAFS Study Group (2009) Functional endoscopic sinus surgery improves asthma symptoms and PEFR and olfaction in patients with nasal polyposis. Allergy 64(5):762–769. https://doi.org/10.1111/j.1398-9995.2008.01870.x Epub 2009 Feb 2. PMID: 19191775
doi: 10.1111/j.1398-9995.2008.01870.x
pubmed: 19191775
Greisner WA 3, Settipane RJ, Settipane GA (2000) Nov-Dec;21(6):371-5 The course of asthma parallels that of allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. https://doi.org/10.2500/108854100778249123 . PMID: 11191104
Seo Y, Nonaka M, Yamamura Y, Pawankar R, Tagaya E (2018) Optimal asthma control improved eosinophilic otitis media. Asia Pac Allergy 8(1):e5. https://doi.org/10.5415/apallergy.2018.8.e5 . PMID: 29423372; PMCID: PMC5796965
doi: 10.5415/apallergy.2018.8.e5
pubmed: 29423372
pmcid: 5796965